Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Socio-economic variations in the mental health treatment gap for people with anxiety, mood, and substance use disorders: results from the WHO World Mental Health (WMH) surveys

  • Evans-Lacko, Sara
  • Alonso Caballero, Jordi
  • Thornicroft, Graham
BACKGROUND:The treatment gap between the number of people with mental disorders and the number treated represents a major public health challenge. We examine this gap by socio-economic status (SES; indicated by family income and respondent education) and service sector in a cross-national analysis of community epidemiological survey data. METHODS: Data come from 16 753 respondents with 12-month DSM-IV disorders from community surveys in 25 countries in the WHO World Mental Health Survey Initiative. DSM-IV anxiety, mood, or substance disorders and treatment of these disorders were assessed with the WHO Composite International Diagnostic Interview (CIDI). RESULTS: Only 13.7% of 12-month DSM-IV/CIDI cases in lower-middle-income countries, 22.0% in upper-middle-income countries, and 36.8% in high-income countries received treatment. Highest-SES respondents were somewhat more likely to receive treatment, but this was true mostly for specialty mental health treatment, where the association was positive with education (highest treatment among respondents with the highest education and a weak association of education with treatment among other respondents) but non-monotonic with income (somewhat lower treatment rates among middle-income respondents and equivalent among those with high and low incomes). CONCLUSIONS: The modest, but nonetheless stronger, an association of education than income with treatment raises questions about a financial barriers interpretation of the inverse association of SES with treatment, although future within-country analyses that consider contextual factors might document other important specifications. While beyond the scope of this report, such an expanded analysis could have important implications for designing interventions aimed at increasing mental disorder treatment among socio-economically disadvantaged people., The World Health Organization World Mental Health (WMH) Survey Initiative is supported by the US National Institute of Mental Health (NIMH; R01 MH070884), the John D. and Catherine T. MacArthur Foundation, the Pfizer Foundation, the US Public Health Service (R13-MH066849, R01-MH069864, and R01 DA016558), the Fogarty International Center (FIRCA R03-TW006481), the Pan American Health Organization, Eli Lilly and Company, Ortho-McNeil Pharmaceutical Inc., GlaxoSmithKline, and Bristol-Myers Squibb. We thank the staff of the WMH Data Collection and Data Analysis Coordination Centres for assistance with instrumentation, fieldwork, and consultation on data analysis. The São Paulo Megacity Mental Health Survey is supported by the State of São Paulo Research Foundation (FAPESP) Thematic Project Grant 03/00204-3. The Bulgarian Epidemiological Study of common mental disorders EPIBUL is supported by the Ministry of Health and the National Center for Public Health Protection. The Chinese World Mental Health Survey Initiative is supported by the Pfizer Foundation. The Shenzhen Mental Health Survey is supported by the Shenzhen Bureau of Health and the Shenzhen Bureau of Science, Technology, and Information. The Colombian National Study of Mental Health (NSMH) is supported by the Ministry of Social Protection. The Mental Health Study Medellín – Colombia was carried out and supported jointly by the Center for Excellence on Research in Mental Health (CES University) and the Secretary of Health of Medellín. The ESEMeD project is funded by the European Commission (Contracts QLG5-1999-01042; SANCO 2004123, and EAHC 20081308), (the Piedmont Region (Italy)), Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Spain (FIS 00/0028), Ministerio de Ciencia y Tecnología, Spain (SAF 2000-158-CE), Departament de Salut, Generalitat de Catalunya, Spain, Instituto de Salud Carlos III (CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP), and other local agencies and by an unrestricted educational grant from GlaxoSmithKline. Implementation of the Iraq Mental Health Survey (IMHS) and data entry was carried out by the staff of the Iraqi MOH and MOP with direct support from the Iraqi IMHS team with funding from both the Japanese and European Funds through United Nations Development Group Iraq Trust Fund (UNDG ITF). The Israel National Health Survey is funded by the Ministry of Health with support from the Israel National Institute for Health Policy and Health Services Research and the National Insurance Institute of Israel. The World Mental Health Japan (WMHJ) Survey is supported by the Grant for Research on Psychiatric and Neurological Diseases and Mental Health (H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013, H25-SEISHIN-IPPAN-006) from the Japan Ministry of Health, Labour and Welfare. The Lebanese Evaluation of the Burden of Ailments and Needs Of the Nation (L.E.B.A.N.O.N.) is supported by the Lebanese Ministry of Public Health, the WHO (Lebanon), National Institute of Health / Fogarty International Center (R03 TW006481-01), anonymous private donations to IDRAAC, Lebanon, and unrestricted grants from, Algorithm, AstraZeneca, Benta, Bella Pharma, Eli Lilly, Glaxo Smith Kline, Lundbeck, Novartis, OmniPharma, Pfizer, Phenicia, Servier, UPO. The Mexican National Comorbidity Survey (MNCS) is supported by The National Institute of Psychiatry Ramon de la Fuente (INPRFMDIES 4280) and by the National Council on Science and Technology (CONACyT-G30544- H), with supplemental support from the PanAmerican Health Organization (PAHO). Te Rau Hinengaro: The New Zealand Mental Health Survey (NZMHS) is supported by the New Zealand Ministry of Health, Alcohol Advisory Council, and the Health Research Council. The Nigerian Survey of Mental Health and Wellbeing (NSMHW) is supported by the WHO (Geneva), the WHO (Nigeria), and the Federal Ministry of Health, Abuja, Nigeria. The Northern Ireland Study of Mental Health was funded by the Health & Social Care Research & Development Division of the Public Health Agency. The Peruvian World Mental Health Study was funded by the National Institute of Health of the Ministry of Health of Peru. The Polish project Epidemiology of Mental Health and Access to Care – EZOP Project (PL 0256) was supported by Iceland, Liechtenstein and Norway through funding from the EEA Financial Mechanism and the Norwegian Financial Mechanism. EZOP project was co-financed by the Polish Ministry of Health. The Portuguese Mental Health Study was carried out by the Department of Mental Health, Faculty of Medical Sciences, NOVA University of Lisbon, with the collaboration of the Portuguese Catholic University, and was funded by Champalimaud Foundation, Gulbenkian Foundation, Foundation for Science and Technology (FCT) and Ministry of Health. The Romania WMH study projects ‘Policies in Mental Health Area’ and ‘National Study regarding Mental Health and Services Use’ were carried out by National School of Public Health & Health Services Management (former National Institute for Research & Development in Health), with technical support of Metro Media Transilvania, the National Institute of Statistics-National Centre for Training in Statistics, SC. Cheyenne Services SRL, Statistics Netherlands and were funded by Ministry of Public Health (former Ministry of Health) with the supplemental support of Eli Lilly Romania SRL. The South Africa Stress and Health Study (SASH) is supported by the US National Institute of Mental Health (R01-MH059575) and National Institute of Drug Abuse with supplemental funding from the South African Department of Health and the University of Michigan. The Psychiatric Enquiry to General Population in Southeast Spain – Murcia (PEGASUSMurcia) Project has been financed by the Regional Health Authorities of Murcia (Servicio Murciano de Salud and Consejería de Sanidad y Política Social) and Fundación para la Formación e Investigación Sanitarias (FFIS) of Murcia. The Ukraine Comorbid Mental Disorders during Periods of Social Disruption (CMDPSD) study is funded by the US National Institute of Mental Health (RO1-MH61905). The US National Comorbidity Survey Replication (NCS-R) is supported by the National Institute of Mental Health (NIMH; U01-MH60220) with supplemental support from the National Institute of Drug Abuse (NIDA), the Substance Abuse and Mental Health Services Administration (SAMHSA), the Robert Wood Johnson Foundation (RWJF; Grant 044708), and the John W. Alden Trust. Dr Evans-Lacko currently holds a Starting Grant from the European Research Council (337673). Dr Thornicroft is supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South London at King’s College London Foundation Trust. GT acknowledges financial support from the Department of Health via the National Institute for Health Research (NIHR) Biomedical Research Centre and Dementia Unit awarded to South London and Maudsley NHS Foundation Trust in partnership with King’s College London and King’s College Hospital NHS Foundation Trust. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. GT is supported by the European Union Seventh Framework Programme (FP7/2007–2013) Emerald project. A complete list of all within-country and cross-national WMH publications can be found at http://www.hcp.med.harvard.edu/wmh/.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Treatment gap for anxiety disorders is global: results of the World Mental Health Surveys in 21 countries

  • Alonso Caballero, Jordi
  • WHO World Mental Health Survey Collaborators
Background: Anxiety disorders are a major cause of burden of disease. Treatment gaps have been described, but a worldwide evaluation is lacking. We estimated, among individuals with a 12‐month DSM‐IV (where DSM is Diagnostic Statistical Manual) anxiety disorder in 21 countries, the proportion who (i) perceived a need for treatment; (ii) received any treatment; and (iii) received possibly adequate treatment. Methods: Data from 23 community surveys in 21 countries of the World Mental Health (WMH) surveys. DSM‐IV mental disorders were assessed (WHO Composite International Diagnostic Interview, CIDI 3.0). DSM‐IV included posttraumatic stress disorder among anxiety disorders, while it is not considered so in the DSM‐5. We asked if, in the previous 12 months, respondents felt they needed professional treatment and if they obtained professional treatment (specialized/general medical, complementary alternative medical, or nonmedical professional) for “problems with emotions, nerves, mental health, or use of alcohol or drugs.” Possibly adequate treatment was defined as receiving pharmacotherapy (1+ months of medication and 4+ visits to a medical doctor) or psychotherapy, complementary alternative medicine or nonmedical care (8+ visits). Results: Of 51,547 respondents (response = 71.3%), 9.8% had a 12‐month DSM‐IV anxiety disorder, 27.6% of whom received any treatment, and only 9.8% received possibly adequate treatment. Of those with 12‐month anxiety only 41.3% perceived a need for care. Lower treatment levels were found for lower income countries. Conclusions: Low levels of service use and a high proportion of those receiving services not meeting adequacy standards for anxiety disorders exist worldwide. Results suggest the need for improving recognition of anxiety disorders and the quality of treatment., The U.S. National Comorbidity Survey Replication (NCS‐R) is supported by the National Institute of Mental Health (NIMH; U01‐MH60220) with supplemental support from the National Institute of Drug Abuse (NIDA), the Substance Abuse and Mental Health Services Administration (SAMHSA). SEL (Sara Evans‐Lacko) currently holds a Starting Grant from the European Research Council (337673). The Robert Wood Johnson Foundation (RWJF; Grant 044708), and the John W. Alden Trust. Dr. Thornicroft is supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South London at King's College London Foundation Trust. Dr. Thornicroft acknowledges support from the following: the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South London at King's College London Foundation Trust; the Department of Health via the National Institute for Health Research (NIHR) Biomedical Research Centre and Dementia Unit awarded to South London and Maudsley NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust; the European Union Seventh Framework Programme (FP7/2007‐2013) Emerald project.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Socio-economic variations in the mental health treatment gap for people with anxiety, mood, and substance use disorders: results from the WHO World Mental Health (WMH) surveys

  • Evans Lacko, Sara
  • Aguilar Gaxiola, Sergio
  • Al-Hamzawi, Ali Obaid
  • Alonso, Jordi
  • Benjet, Corina
  • Bruffaerts, Ronny
  • Chiu, W. T.
  • Florescu, Silvia E.
  • Girolamo, Giovanni de
  • Gureje, Oye
  • Haro Abad, Josep Maria
  • He, Yanling
  • Hu, Chenchung
  • Karam, Elie Georges
  • Kawakami, Norito
  • Lee, Sing
  • Lund, Crick
  • Kovess-Masfety, Viviane
  • Levinson, Daphna
  • Navarro Mateu, Fernando
  • Pennell, Beth-Ellen
  • Sampson, Nancy A.
  • Scott, Kate M. (Kate Margaret), 1960-
  • Tachimori, Hisateru
  • Have, Margreet Ten
  • Viana, Maria Carmen
  • Williams, D. R.
  • Wojtyniak, Bogdan J.
  • Zarkov, Zahari
  • Kessler, Ronald C.
  • Chatterji, Somnath
  • Thornicroft, Graham
Abstract BACKGROUND: The treatment gap between the number of people with mental disorders and the number treated represents a major public health challenge. We examine this gap by socio-economic status (SES; indicated by family income and respondent education) and service sector in a cross-national analysis of community epidemiological survey data. METHODS: Data come from 16 753 respondents with 12-month DSM-IV disorders from community surveys in 25 countries in the WHO World Mental Health Survey Initiative. DSM-IV anxiety, mood, or substance disorders and treatment of these disorders were assessed with the WHO Composite International Diagnostic Interview (CIDI). RESULTS: Only 13.7% of 12-month DSM-IV/CIDI cases in lower-middle-income countries, 22.0% in upper-middle-income countries, and 36.8% in high-income countries received treatment. Highest-SES respondents were somewhat more likely to receive treatment, but this was true mostly for specialty mental health treatment, where the association was positive with education (highest treatment among respondents with the highest education and a weak association of education with treatment among other respondents) but non-monotonic with income (somewhat lower treatment rates among middle-income respondents and equivalent among those with high and low incomes). CONCLUSIONS: The modest, but nonetheless stronger, an association of education than income with treatment raises questions about a financial barriers interpretation of the inverse association of SES with treatment, although future within-country analyses that consider contextual factors might document other important specifications. While beyond the scope of this report, such an expanded analysis could have important implications for designing interventions aimed at increasing mental disorder treatment among socio-economically disadvantaged people.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Treatment gap for anxiety disorders is global: Results of the World Mental Health Surveys in 21 countries

  • Alonso Caballero, Jordi
  • Liu, Zhaorui
  • Evans Lacko, Sara
  • Sadikova, Ekaterina
  • Sampson, Nancy A.
  • Chatterji, Somnath
  • Abdulmalik, Jibril
  • Aguilar Gaxiola, Sergio
  • Al-Hamzawi, Ali Obaid
  • Andrade, Laura Helena
  • Bruffaerts, Ronny
  • Cardoso, Graça
  • Cia, Alfredo H.
  • Florescu, Silvia E.
  • Girolamo, Giovanni de
  • Gureje, Oye
  • Haro Abad, Josep Maria
  • He, Yanling
  • Jonge, Peter de
  • Karam, Elie Georges
  • Kawakami, Norito
  • Kovess-Masfety, Viviane
  • Lee, Sing
  • Levinson, Daphna
  • Medina Mora, Maria Elena
  • Navarro Mateu, Fernando
  • Pennell, Beth-Ellen
  • Piazza, Marina
  • Posada Villa, José
  • Have, Margreet ten
  • Zarkov, Zahari
  • Kessler, Ronald C.
  • Thornicroft, Graham
  • WHO World Mental Health Survey Collaborators
Abstract BACKGROUND: Anxiety disorders are a major cause of burden of disease. Treatment gaps have been described, but a worldwide evaluation is lacking. We estimated, among individuals with a 12-month DSM-IV (where DSM is Diagnostic Statistical Manual) anxiety disorder in 21 countries, the proportion who (i) perceived a need for treatment; (ii) received any treatment; and (iii) received possibly adequate treatment. METHODS: Data from 23 community surveys in 21 countries of the World Mental Health (WMH) surveys. DSM-IV mental disorders were assessed (WHO Composite International Diagnostic Interview, CIDI 3.0). DSM-IV included posttraumatic stress disorder among anxiety disorders, while it is not considered so in the DSM-5. We asked if, in the previous 12 months, respondents felt they needed professional treatment and if they obtained professional treatment (specialized/general medical, complementary alternative medical, or nonmedical professional) for 'problems with emotions, nerves, mental health, or use of alcohol or drugs.' Possibly adequate treatment was defined as receiving pharmacotherapy (1+ months of medication and 4+ visits to a medical doctor) or psychotherapy, complementary alternative medicine or nonmedical care (8+ visits). RESULTS: Of 51,547 respondents (response = 71.3%), 9.8% had a 12-month DSM-IV anxiety disorder, 27.6% of whom received any treatment, and only 9.8% received possibly adequate treatment. Of those with 12-month anxiety only 41.3% perceived a need for care. Lower treatment levels were found for lower income countries. CONCLUSIONS: Low levels of service use and a high proportion of those receiving services not meeting adequacy standards for anxiety disorders exist worldwide. Results suggest the need for improving recognition of anxiety disorders and the quality of treatment.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The exposome of brain aging across 34 countries

  • Legaz, Agustina
  • Moguilner, Sebastian
  • Barttfeld, Pablo
  • Cuadros Castro, Jhosmary
  • Galván Rial, Dante Sebastián
  • Migeot, Joaquín
  • Farina, Francesca R.
  • González-Gómez, Raúl
  • Salazar-Londoño, Salomón
  • de Souza Azzi, Tiago
  • Alcauter, Sarael
  • Amoruso, Lucía
  • Anghinah, Renato
  • Bakr, May
  • Behrens, María Isabel
  • Bruno, Martín A.
  • Cardona, Juan Felipe
  • Chen, Christopher
  • Colliot, Olivier
  • Custodio, Nilton
  • d'Acremont, Quentin
  • Debette, Stéphanie
  • Dzianok, Patrycja
  • Güntekin, Bahar
  • Huguet, Jordi
  • Jarne, Cecilia
  • Joliot, Marc
  • Karageorgiou, Elissaios
  • Khedr, Eman M.
  • Koopowitz, Sheri-Michelle
  • Kublik, Ewa
  • Lee, Jinkook
  • Aksman, Leon
  • López, Susanna
  • Margaretic, Paula
  • Matallana, Diana
  • Matis, Sophie
  • Miltiadous, Andreas
  • Novotni, Gabriela
  • Orio, Patricio
  • Parra, Mario A.
  • Reppermund, Simone
  • de Paula França Resende, Elisa
  • Salum, Giovanni Abrahão
  • Slachevsky, Andrea
  • Sosa Ortiz, Ana Luisa
  • Tadao Takada, Leonel
  • Toh, An Qi
  • Tzallas, Alexandros
  • Wen, Wei
  • Whelan, Robert
  • Yener, Görsev
  • Zegarra Valdivia, Jonathan Adrián
  • Alexoudi, Athanasia
  • Arshad, Faheem
  • Atta, Haisam
  • Ávila-Funes, José Alberto
  • Bonilla Santos, Jasmin
  • Bruña, Ricardo
  • Castelblanco-Toro, Sandra Milena
  • Chino Vilca, Brenda Nadia
  • Coronel-Oliveros, Carlos
  • Crivello, Fabrice
  • Cruzat, Josephine
  • Dellavale, Damián
  • Dhooge, Catherina
  • Di Caterina, Gaetano
  • Escudero, Javier
  • Esquivias Farias, Juan Manuel
  • Eze, Laz Ude
  • Evans, Tavia E.
  • Farombi, Temitope
  • Fernández, Alberto
  • Fittipaldi, Sol
  • Portillo, Florencia
  • Forno Martinic, Gonzalo
  • García, Adolfo M.
  • Garcia-Cordero, Indira
  • Gaurav, Rahul
  • Godoy, Maria Eugenia
  • González Campo, Cecilia
  • González Hernández, Alfredis
  • Hanoğlu, Lütfü
  • Hazelton, Jessica L.
  • Herzog, Rubén
  • Ikiz, Burcin
  • Njamnshi, Alfred Kongnyu
  • Landín-Romero, Ramón
  • López, María Eugenia
  • Maito, Marcelo Adrián
  • Medel, Vicente
  • Sepúlveda, Juan Pablo Morales
  • Ochoa Gómez, John Fredy
  • Ogbuagu, Chukwuanugo
  • de Oliveira, Maira Okada
  • Ozansoy, Mehmet
  • Palma-Espinosa, Javier
  • Hilal, Saima
  • Zhou, Juan Helen
  • Piña Escudero, Stefanie Danielle
  • Pitman, Julie Kay
  • Prado, Pavel
  • Ramírez González, Diego
  • Reyes, Pablo
  • Santamaría García, Hernando
  • Schröder, Johannes
  • Sitt, Jacobo Diego
  • Soliman, Radwa Kamel
  • Soto-Añari, Marcio
  • Thanissery, Nithin
  • Ito, Lucas Toshio
  • Tsuchida, Ami
  • Tzourio, Christophe
  • Yırıkoğulları, Harun
  • Yokoyama, Jennifer S.
  • Aguillón, David
  • Miller, Bruce
  • Alladi, Suvarna
  • Jiang, Yang
  • Navarro, Arcadi
  • Babiloni, Claudio
  • Huepe Artigas, David
  • Piguet, Olivier
  • Valdes Sosa, Pedro Antonio
  • Mostert, Cyprian M.
  • Tahmasian, Masoud
  • Li, Peng
  • Hu, Kun
  • Genon, Sarah
  • Stein, Dan J.
  • Maestú, Fernando
  • Pievani, Michela
  • Salama, Mohamed
  • Brodaty, Henry
  • Sachdev, Perminder S.
  • Lawlor, Brian
  • Eyre, Harris A.
  • Miranda, J. Jaime
  • Baez, Sandra
  • Tagliazucchi, Enzo
  • Durán-Aniotz, Claudia
  • Hernandez, Hernan
  • Ibáñez, Agustín
The physical and social exposome affects human aging, and brain clocks may track its effects. However, most studies neglect multidomain exposures (physical, social and political) across diverse settings globally and their associations with brain aging. In this study, we characterized the associations between 73 country-level physical and social exposomal factors and multimodal brain age in 18,701 participants from 34 countries (healthy individuals and those with Alzheimer's disease, frontotemporal lobar degeneration or mild cognitive impairment). Exposome effects were assessed using generalized additive models and meta-analytic frameworks. Aggregated exposome models explained up to 15.5-fold more variance than individual exposures (delta Akaike information criterion (ΔAIC): 2,034-3,127). Physical exposome was primarily associated with accelerated structural brain aging (limbic, subcortical and cerebellar regions), whereas social exposome was more strongly associated with functional brain aging (frontotemporal and limbic networks). Exposome burden accounted for 3.3-9.1-fold higher risk of accelerated aging, exceeding effects of clinical diagnoses. Findings were out-of-sample validated in cross-sectional and longitudinal designs, remained consistent across clinical subgroups and persisted after adjustment for demographics, age correction bias, cognition, scanner type and data quality. The exposome accelerates brain aging in health and disease, underscoring the need to address physical, social and political inequities., A.L. is supported by a ReDLat-NIH postdoctoral position and an Atlantic Fellowship from the Global Brain Health Institute (GBHI). H.H. is supported by the Davos Alzheimer’s Collaborative. F.F. is supported by an Alzheimer’s Association Research Fellowship Grant (AARF-21-848281). S.A. is supported by IN212624, PAPIIT-DGAPA-UNAM IN208622 y SECIHTI CF-2019/6390. L.A. is supported by the European Union’s Horizon 2020 research and innovation program under Marie Sklodowska-Curie grant agreement number 101025814. M.I.B. is supported by National Institute on Drug Abuse 75N95022C00031: Genetics of Alzheimer’s Disease and Related Dementias in Latin America. M.I.B. is also co-investigator for SG-20-725707-ReDLat, Alzheimer’s Association, Multi-partner Consortium for Dementia Research in Latin America. O.C. is supported by the French government under management of Agence Nationale de la Recherche as part of the ‘France 2030’ program (reference ANR-23-IACL-0008, project PRAIRIE-PSAI), as part of the ‘Investissements d’avenir’ program (reference ANR-19-P3IA-0001, project PRAIRIE 3IA Institute and reference ANR-10-IAIHU-06, project Agence Nationale de la Recherche-10-IA Institut Hospitalo-Universitaire-6), and by the European Union’s Horizon Europe Framework Program (grant number 101136607, project CLARA). N.C. is supported by ReDLat-NIH (AG057234). S.D. is supported by a grant overseen by the French National Research Agency (ANR) as part of the France 2030 ‘Investment for the Future Programme’ through the SHIVA project (ANR-18-RHUS-0002) and through the Precision and Global Vascular Brain Health Institute, funded by the France 2030 IHU3 initiative (ANR-23-IAHU-0001). Computations were performed at the Bordeaux Bioinformatics Center (CBiB) and the CREDIM computer resources, University of Bordeaux. Funding support for additional computer resources has been provided to S.D. by the Fondation Claude Pompidou. C.C. is supported by the National Medical Research Council of Singapore. The i-Share study has received funding from the French National Agency (Agence Nationale de la Recherche (ANR)), via the Investment for the Future program (grant no. ANR-10-COHO-05 and no. ANR-18-RHUS-0002) and from the University of Bordeaux Initiative of Excellence (IdEX). P.D. is supported by Polish National Science Center (NCN) grant number 2018/31/N/HS6/03551. C.J. is supported by UNQ, Proyecto de I+D Res.745/25. E.K. is supported by the MES-CoBraD Project EU Horizon 2020 grant (ID: 965422) to the Neurological Institute of Athens. J.L. is supported by the US National Institute on Aging (NIA), National Institutes of Health (NIH) (R01AG051125 and U01AG064948). L.A. is supported by the Office of the Director, NIH, under award numbers S10OD032285, R01AG080473, RF1AG087965 and RF1AG088003. (The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.) J.H.Z. is supported by the Singapore National Medical Research Council, grant numbers NMRC/OFLCG19May-0035, HLCA23Feb-0004 and OFIRG24Jul-0049. S.L. is supported by the ‘BE FOR ERC 2023’ fellowship from Sapienza University of Rome. P.M. is supported by the Belmon Forum. G.N. would like to extend her gratitude to V. Aliji from the University Institute of Radiology-Skopje, North Macedonia, and the Neurophysiology team from the University Clinic of Neurology, Skopje, North Macedonia, for their cooperation. P.O. is supported by Proyecto Fondecyt 1241469, ANID, Chile, and Proyecto AFB240002, ANID, Chile. M.A.P. is supported by a BrainLat Seed Grant (BL-SRGP2020-020) awarded to M.A.P. and A.I. E.d.P.F.R. is supported by the NIA of the NIH (R21AG069252), the Alzheimer’s Association (GBHI_ALZ-18-534892) and the World Federation of Neurology. G.A.S.J. is supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq grant numbers 573974/2008-0 and 465550/2014-2); Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP grant numbers 2008/57896-8, 2013/08531-5, 2014/50917-0, 2020/06172-1, 2021/05332-8 and 2021/12901-9); the European Research Council (ERC grant numbers 337673 and 101057390); the UK Medical Research Council (MRC grant number MR/R022763/1); Ministério da Saúde (Decit/SECTICS/MS grant number 888379/2019, Portaria no. 1.949, 04/08/2020); and Banco Industrial do Brasil S/A (CISM grant). A.S. is supported by ANID/Fondap/15150012, ANID/Fondecyt/1231839, ANID/FONDEF/ID22I10251 and ANID/Proyectos de Exploración 13220082 and ReDLat (supported by NIA, NIH (R01 AG057234), the Alzheimer’s Association (SG-20-725707), the Tau Consortium and the GBHI) and by Alzheimer’s Association GBHI ALZ UK-20-639295. L.T.T. is supported by the NIH (ReDLat). J.C. is supported by ANID (FONDECYT Postdoctorado no. 3240042 and Proyectos de Exploración no. 13240170). R.H. is supported by the Spanish Ministerio de Ciencia, Innovación y Universidades (MICIU/AEI/10.13039/501100011033) through María de Maeztu project CEX2021-001164-M. G.F.M. is supported by ANID (Fondecyt Postdoctoral no. 3250669). A.M.G. is partially supported by the NIA of the NIH (R01AG075775, R01AG083799 and 2P01AG019724); ANID (FONDECYT Regular 1250317 and 1250091); DICYT-USACH (032351GDAS); Agencia Nacional de Promoción Científica y Tecnológica (01-PICTE-2022-05-00103); and the ReDLat, which is supported by the Fogarty International Center and the NIH, NIA (R01AG057234, R01AG075775, R01AG21051 and CARDA-NIH), the Alzheimer’s Association (SG-20-725707), the Rainwater Charitable Foundation’s Tau Consortium, the Bluefield Project to Cure Frontotemporal Dementia and the GBHI. I.G.-C. is supported by an AFTD Pathways for Hope Pilot Grant (2025-002). R.L.-R. is supported by a National Health and Medical Research Council (NHMRC) Investigator Grant (GNT2010064). M.E.L. is supported by I+D+i project PID2022-141524NA-I00, funded by MCIN/AEI/10.13039/501100011033. V.M. is supported by ANID/FONDECYT de Iniciación 11251578 and ANID/FONDECYT Exploración 13240170. D.R.G. is supported by Fellowship 1003248 from Secretaría de Ciencia, Humanidades, Tecnología e Innovación (SECIHTI). H.S.G. is supported by an NIH R01 grant (‘Social epigenetics of Alzheimer’s disease and related dementias in Latin American countries’ (1R01AG082056-01A1)), the GBHI and the Alzheimerʼs Association (‘Brain health in individuals with exposition to high violence in Colombia’ (GBHI ALZ UK-23-971135)). J.E. acknowledges support from the UKRI AI program and the Engineering and Physical Sciences Research Council, for the CHAI-EPSRC AI hub for Causality in Healthcare AI with real data (grant number EP/Y028856/1). J.D.S. is supported by Program Investissements d’avenir ANR-10-IAIHU-06. M.S.-A. is supported by CONCYTEC (contrato no. PE501082737-2023-PROCIENCIA). L.T.I. is supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, grant number 2022/15880-5). A.T. is supported by Investment for the Future Programme France 2030 (grant no. ANR-18-RHUS-0002) and the France 2030 IHU3 initiative for the Precision and Global Vascular Brain Health Institute (grant ANR-23-IAHU-0001). Y.J. is supported by NIA, NIH P01AG078116 and P30AG072946. (Data curation was partially supported by NIH grant AG000986 and Department of Energy contract DE-AC05-00OR22725.) C.B. is supported by funds of the project ‘Rome Technopole’ from the call Piano Nazionale di Ripresa e Resilienza (PNRR), Mission 4, ‘Istruzione e Ricerca’, Component 2, ‘Investment 1.5’, granted by the European Union, Next Generation EU and the Italian Ministry of University and Research (grant agreement ECS00000024). J.B.S. is supported by CONADI-Universidad Cooperativa de Colombia. D.H. is supported by ANID/FONDECYT Regular number 1231117. O.P. is supported by an NHMRC of Australia program grant (GNT1037746) and a Leadership Fellowship (GNT2008020) and by the Australian Research Council Centre of Excellence in Cognition and its Disorders Memory Program (CE11000102). P.A.V.S. is supported by the National Key R&D Program of China (2024YFE and 0215100). S.G. is supported by the Deutsche Forschungsgemeinschaft (DFG, GE 2835/2–1 and GE 2835/9-1). D.J.S. was supported by the SAMRC. F.M. is supported by Spanish Ministry of Science PID2021-122979OB-C21. M.P. is supported by the IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli and acknowledges support from the Italian Ministry of Health (Ricerca Corrente). The principal investigator of ARWIBO is G. B. Frisoni, University Hospitals and University of Geneva, Geneva, Switzerland, and IRCCS Fatebenefratelli, the National Centre for Alzheimer’s and Mental Diseases, Brescia, Italy. ARWIBO is the result of efforts of many researchers of IRCCS Fatebenefratelli: G. Binetti, Neurobiology; L. Bocchio-Chiavetto, Neuropharmacology; M. Cotelli, Neuropsychology; C. Minussi, Neurophysiology; M. Gennarelli, Genetic Unit; R. Ghidoni, Proteomics Unit; and D. Moretti and O. Zanetti, Alzheimer’s Unit. Data collection and sharing for ARWIBO was supported by the Italian Ministry of Health under the following grant agreements: Ricerca Corrente IRCCS Fatebenefratelli, Linea di Ricerca 2; Progetto Finalizzato Strategico 2000−2001 ‘Archivio normativo italiano di morfometria cerebrale con risonanza magnetica (età 40+)’; Progetto Finalizzato Strategico 2000−2001 ‘Decadimento cognitivo lieve non dementigeno: stadio preclinico di malattia di Alzheimer e demenza vascolare. Caratterizzazione clinica, strumentale, genetica e neurobiologica e sviluppo di criteri diagnostici utilizzabili nella realtà nazionale’; Progetto Finalizzata 2002 ‘Sviluppo di indicatori di danno cerebrovascolare clinicamente significativo alla risonanza magnetica strutturale’; Progetto Fondazione CARIPLO 2005−2007 ‘Geni di suscettibilità per gli endofenotipi associati a malattie psichiatriche e dementigene’; ‘Fitness and Solidarietà’; and anonymous donors. M.S. is supported by the NIA (grant 1R01AG081305); Davos Alzheimer’s Collaborative grant DAC-GC-22240710.01; the Doha International Family Institute (grant OSRA6-G-202305-00052); and American University in Cairo Research Support Grant 2022. H.B. has received funding from the NHMRC. P.S.S. is supported by an NHMRC of Australia Investigator Grant (RG193540), an NHMRC CRE grant (RG203943) and an NIH grant (R01AG057531-03). The Sydney Memory and Ageing Study has been funded by three NHMRC program grants (ID350833, ID568969 and APP1093083). J.J.M. is supported by the Academy of Medical Sciences (NGR2/1210); the Alliance for Health Policy and Systems Research (2009/32034 and 2012/253750); Bloomberg Philanthropies (grant 46129, via University of North Carolina at Chapel Hill School of Public Health); FONDECYT via CIENCIACTIVA/CONCYTEC, the British Council, the British Embassy and the Newton-Paulet Fund (223-2018 and 224-2018); DFID/MRC/Wellcome Global Health Trials (MR/M007405/1); the Fogarty International Center (R21TW009982, D71TW010877, R21TW011740 and K01TW011478); Grand Challenges Canada (GMH-POC-0335-04); the International Development Research Center Canada (IDRC 106887 and 108167); the Inter-American Institute for Global Change Research (IAI CRN3036); the National Cancer Institute (NCI 1P20CA217231); the National Council for Scientific and Technological Development (CNPq Brasil 408523/2023-9); the NHMRC (2022036, 2022566 and 2044237); the National Heart, Lung, and Blood Institute (NHLBI HHSN268200900033C, 5U01HL114180 and 1UM1HL134590); the NIA (R01AG057531); the National Institute for Health and Care Research (NIHR150261, NIHR150287, NIHR303125 and NIHR306208); the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK K23DK135798); the National Institute of Mental Health (NIMH 1U19MH098780); NSW Health (H23/37663 and DG23/7050); the Medical Research Future Fund (MRRF 204223); the Swiss National Science Foundation (40P740-160366); UKRI BBSRC (BB/T009004/1); UKRI EPSRC (EP/V043102/1); UKRI MRC (MR/P008984/1, MR/P024408/1, MR/P02386X/1, MR/X004163/1 and MR/X020851/1); Wellcome (074833/Z/04/Z, 093541/Z/10/Z, 103994/Z/14/Z, 107435/Z/15/Z, 205177/Z/16/Z, 214185/Z/18/Z and 218743/Z/19/Z); the World Diabetes Foundation (WDF15-1224); and the World Health Organization (2021/1189041 and 2022/1249357). T.E. is supported by the William H. Gates Sr. Fellowship from the Alzheimer’s Disease Data Initiative and Alzheimer Nederland Project WE.03-2024-07. S.B. is supported by the GBHI, the Alzheimer’s Association, Alzheimer’s Society UK and Pilot Awards for Global Brain Health Leaders (grant GBHI ALZ UK- 25-1289623). E.T. is supported by ANID/FONDECYT Regular 1220995 (Chile), ‘Mapping and modeling healthy and pathological aging trajectories’ and FONDECYT Exploración 13240170 ‘Neurovascular pathways in aging and neurodegenerative diseases: integrating cardiovascular health and brain function’. C.D.-A. is supported by ANID/FONDECYT Regular 1210622, ANID/PIA/ANILLOS ACT210096, the Alzheimer’s Association (AARGD-24- 1310017), ANID/FOVI240065 and ANID/Proyecto Exploracion 13240170. A.I. is supported by grants from the ReDLat (supported by the Fogarty International Center, the NIH, NIA (R01 AG057234, R01 AG075775, R01 AG21051, R01 AG083799, CARDS-NIH and R01 AG057234), the Alzheimer’s Association (SG-20-725707), the Rainwater Charitable Foundation, the Bluefield Project to Cure Frontotemporal Dementia and the GHBI); ANID/FONDECYT Regular (1250091, 1210176 and 1220995); ANID/PIA/ANILLOS ACT210096; JPI JPND-Care, DISCeRN 2025: Health and Social Care Research with a Focus on the Moderate and Late Stages of Neurodegenerative Diseases; FONDEF ID20I10152 and ANID/FONDAP 15150012; Wellcome Trust award for BRAIN-CLIMA: Investigating the Combined Impact of Heat and Air Pollution on Blood−Brain Barrier Integrity and Brain Aging in Latin America (335293/Z/25/Z); and CliCBrain (Horizon ID: 101236426; https://doi.org/10.3030/101236426, Marie Skłodowska-Curie Actions)., With funding from the Spanish government through the "Maria de Maeztu Centre of Excellence" accreditation (CEX2021-001164-M)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Socio-economic variations in the mental health treatment gap for people with anxiety, mood, and substance use disorders: results from the WHO World Mental Health (WMH) surveys

  • Evans Lacko, Sara
  • Aguilar Gaxiola, Sergio
  • Al-Hamzawi, Ali Obaid
  • Alonso, Jordi
  • Benjet, Corina
  • Bruffaerts, Ronny
  • Chiu, W. T.
  • Florescu, Silvia E.
  • Girolamo, Giovanni de
  • Gureje, Oye
  • Haro Abad, Josep Maria
  • He, Yanling
  • Hu, Chenchung
  • Karam, Elie Georges
  • Kawakami, Norito
  • Lee, Sing
  • Lund, Crick
  • Kovess-Masfety, Viviane
  • Levinson, Daphna
  • Navarro Mateu, Fernando
  • Pennell, Beth-Ellen
  • Sampson, Nancy A.
  • Scott, Kate M. (Kate Margaret), 1960-
  • Tachimori, Hisateru
  • Have, Margreet Ten
  • Viana, Maria Carmen
  • Williams, D. R.
  • Wojtyniak, Bogdan J.
  • Zarkov, Zahari
  • Kessler, Ronald C.
  • Chatterji, Somnath
  • Thornicroft, Graham
Abstract BACKGROUND: The treatment gap between the number of people with mental disorders and the number treated represents a major public health challenge. We examine this gap by socio-economic status (SES; indicated by family income and respondent education) and service sector in a cross-national analysis of community epidemiological survey data. METHODS: Data come from 16 753 respondents with 12-month DSM-IV disorders from community surveys in 25 countries in the WHO World Mental Health Survey Initiative. DSM-IV anxiety, mood, or substance disorders and treatment of these disorders were assessed with the WHO Composite International Diagnostic Interview (CIDI). RESULTS: Only 13.7% of 12-month DSM-IV/CIDI cases in lower-middle-income countries, 22.0% in upper-middle-income countries, and 36.8% in high-income countries received treatment. Highest-SES respondents were somewhat more likely to receive treatment, but this was true mostly for specialty mental health treatment, where the association was positive with education (highest treatment among respondents with the highest education and a weak association of education with treatment among other respondents) but non-monotonic with income (somewhat lower treatment rates among middle-income respondents and equivalent among those with high and low incomes). CONCLUSIONS: The modest, but nonetheless stronger, an association of education than income with treatment raises questions about a financial barriers interpretation of the inverse association of SES with treatment, although future within-country analyses that consider contextual factors might document other important specifications. While beyond the scope of this report, such an expanded analysis could have important implications for designing interventions aimed at increasing mental disorder treatment among socio-economically disadvantaged people.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Treatment gap for anxiety disorders is global: results of the World Mental Health Surveys in 21 countries

  • Alonso Caballero, Jordi
  • WHO World Mental Health Survey Collaborators
Background: Anxiety disorders are a major cause of burden of disease. Treatment gaps have been described, but a worldwide evaluation is lacking. We estimated, among individuals with a 12‐month DSM‐IV (where DSM is Diagnostic Statistical Manual) anxiety disorder in 21 countries, the proportion who (i) perceived a need for treatment; (ii) received any treatment; and (iii) received possibly adequate treatment. Methods: Data from 23 community surveys in 21 countries of the World Mental Health (WMH) surveys. DSM‐IV mental disorders were assessed (WHO Composite International Diagnostic Interview, CIDI 3.0). DSM‐IV included posttraumatic stress disorder among anxiety disorders, while it is not considered so in the DSM‐5. We asked if, in the previous 12 months, respondents felt they needed professional treatment and if they obtained professional treatment (specialized/general medical, complementary alternative medical, or nonmedical professional) for “problems with emotions, nerves, mental health, or use of alcohol or drugs.” Possibly adequate treatment was defined as receiving pharmacotherapy (1+ months of medication and 4+ visits to a medical doctor) or psychotherapy, complementary alternative medicine or nonmedical care (8+ visits). Results: Of 51,547 respondents (response = 71.3%), 9.8% had a 12‐month DSM‐IV anxiety disorder, 27.6% of whom received any treatment, and only 9.8% received possibly adequate treatment. Of those with 12‐month anxiety only 41.3% perceived a need for care. Lower treatment levels were found for lower income countries. Conclusions: Low levels of service use and a high proportion of those receiving services not meeting adequacy standards for anxiety disorders exist worldwide. Results suggest the need for improving recognition of anxiety disorders and the quality of treatment., The U.S. National Comorbidity Survey Replication (NCS‐R) is supported by the National Institute of Mental Health (NIMH; U01‐MH60220) with supplemental support from the National Institute of Drug Abuse (NIDA), the Substance Abuse and Mental Health Services Administration (SAMHSA). SEL (Sara Evans‐Lacko) currently holds a Starting Grant from the European Research Council (337673). The Robert Wood Johnson Foundation (RWJF; Grant 044708), and the John W. Alden Trust. Dr. Thornicroft is supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South London at King's College London Foundation Trust. Dr. Thornicroft acknowledges support from the following: the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South London at King's College London Foundation Trust; the Department of Health via the National Institute for Health Research (NIHR) Biomedical Research Centre and Dementia Unit awarded to South London and Maudsley NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust; the European Union Seventh Framework Programme (FP7/2007‐2013) Emerald project.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Socio-economic variations in the mental health treatment gap for people with anxiety, mood, and substance use disorders: results from the WHO World Mental Health (WMH) surveys

  • Evans-Lacko, Sara
  • Alonso Caballero, Jordi
  • Thornicroft, Graham
BACKGROUND:The treatment gap between the number of people with mental disorders and the number treated represents a major public health challenge. We examine this gap by socio-economic status (SES; indicated by family income and respondent education) and service sector in a cross-national analysis of community epidemiological survey data. METHODS: Data come from 16 753 respondents with 12-month DSM-IV disorders from community surveys in 25 countries in the WHO World Mental Health Survey Initiative. DSM-IV anxiety, mood, or substance disorders and treatment of these disorders were assessed with the WHO Composite International Diagnostic Interview (CIDI). RESULTS: Only 13.7% of 12-month DSM-IV/CIDI cases in lower-middle-income countries, 22.0% in upper-middle-income countries, and 36.8% in high-income countries received treatment. Highest-SES respondents were somewhat more likely to receive treatment, but this was true mostly for specialty mental health treatment, where the association was positive with education (highest treatment among respondents with the highest education and a weak association of education with treatment among other respondents) but non-monotonic with income (somewhat lower treatment rates among middle-income respondents and equivalent among those with high and low incomes). CONCLUSIONS: The modest, but nonetheless stronger, an association of education than income with treatment raises questions about a financial barriers interpretation of the inverse association of SES with treatment, although future within-country analyses that consider contextual factors might document other important specifications. While beyond the scope of this report, such an expanded analysis could have important implications for designing interventions aimed at increasing mental disorder treatment among socio-economically disadvantaged people., The World Health Organization World Mental Health (WMH) Survey Initiative is supported by the US National Institute of Mental Health (NIMH; R01 MH070884), the John D. and Catherine T. MacArthur Foundation, the Pfizer Foundation, the US Public Health Service (R13-MH066849, R01-MH069864, and R01 DA016558), the Fogarty International Center (FIRCA R03-TW006481), the Pan American Health Organization, Eli Lilly and Company, Ortho-McNeil Pharmaceutical Inc., GlaxoSmithKline, and Bristol-Myers Squibb. We thank the staff of the WMH Data Collection and Data Analysis Coordination Centres for assistance with instrumentation, fieldwork, and consultation on data analysis. The São Paulo Megacity Mental Health Survey is supported by the State of São Paulo Research Foundation (FAPESP) Thematic Project Grant 03/00204-3. The Bulgarian Epidemiological Study of common mental disorders EPIBUL is supported by the Ministry of Health and the National Center for Public Health Protection. The Chinese World Mental Health Survey Initiative is supported by the Pfizer Foundation. The Shenzhen Mental Health Survey is supported by the Shenzhen Bureau of Health and the Shenzhen Bureau of Science, Technology, and Information. The Colombian National Study of Mental Health (NSMH) is supported by the Ministry of Social Protection. The Mental Health Study Medellín – Colombia was carried out and supported jointly by the Center for Excellence on Research in Mental Health (CES University) and the Secretary of Health of Medellín. The ESEMeD project is funded by the European Commission (Contracts QLG5-1999-01042; SANCO 2004123, and EAHC 20081308), (the Piedmont Region (Italy)), Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Spain (FIS 00/0028), Ministerio de Ciencia y Tecnología, Spain (SAF 2000-158-CE), Departament de Salut, Generalitat de Catalunya, Spain, Instituto de Salud Carlos III (CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP), and other local agencies and by an unrestricted educational grant from GlaxoSmithKline. Implementation of the Iraq Mental Health Survey (IMHS) and data entry was carried out by the staff of the Iraqi MOH and MOP with direct support from the Iraqi IMHS team with funding from both the Japanese and European Funds through United Nations Development Group Iraq Trust Fund (UNDG ITF). The Israel National Health Survey is funded by the Ministry of Health with support from the Israel National Institute for Health Policy and Health Services Research and the National Insurance Institute of Israel. The World Mental Health Japan (WMHJ) Survey is supported by the Grant for Research on Psychiatric and Neurological Diseases and Mental Health (H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013, H25-SEISHIN-IPPAN-006) from the Japan Ministry of Health, Labour and Welfare. The Lebanese Evaluation of the Burden of Ailments and Needs Of the Nation (L.E.B.A.N.O.N.) is supported by the Lebanese Ministry of Public Health, the WHO (Lebanon), National Institute of Health / Fogarty International Center (R03 TW006481-01), anonymous private donations to IDRAAC, Lebanon, and unrestricted grants from, Algorithm, AstraZeneca, Benta, Bella Pharma, Eli Lilly, Glaxo Smith Kline, Lundbeck, Novartis, OmniPharma, Pfizer, Phenicia, Servier, UPO. The Mexican National Comorbidity Survey (MNCS) is supported by The National Institute of Psychiatry Ramon de la Fuente (INPRFMDIES 4280) and by the National Council on Science and Technology (CONACyT-G30544- H), with supplemental support from the PanAmerican Health Organization (PAHO). Te Rau Hinengaro: The New Zealand Mental Health Survey (NZMHS) is supported by the New Zealand Ministry of Health, Alcohol Advisory Council, and the Health Research Council. The Nigerian Survey of Mental Health and Wellbeing (NSMHW) is supported by the WHO (Geneva), the WHO (Nigeria), and the Federal Ministry of Health, Abuja, Nigeria. The Northern Ireland Study of Mental Health was funded by the Health & Social Care Research & Development Division of the Public Health Agency. The Peruvian World Mental Health Study was funded by the National Institute of Health of the Ministry of Health of Peru. The Polish project Epidemiology of Mental Health and Access to Care – EZOP Project (PL 0256) was supported by Iceland, Liechtenstein and Norway through funding from the EEA Financial Mechanism and the Norwegian Financial Mechanism. EZOP project was co-financed by the Polish Ministry of Health. The Portuguese Mental Health Study was carried out by the Department of Mental Health, Faculty of Medical Sciences, NOVA University of Lisbon, with the collaboration of the Portuguese Catholic University, and was funded by Champalimaud Foundation, Gulbenkian Foundation, Foundation for Science and Technology (FCT) and Ministry of Health. The Romania WMH study projects ‘Policies in Mental Health Area’ and ‘National Study regarding Mental Health and Services Use’ were carried out by National School of Public Health & Health Services Management (former National Institute for Research & Development in Health), with technical support of Metro Media Transilvania, the National Institute of Statistics-National Centre for Training in Statistics, SC. Cheyenne Services SRL, Statistics Netherlands and were funded by Ministry of Public Health (former Ministry of Health) with the supplemental support of Eli Lilly Romania SRL. The South Africa Stress and Health Study (SASH) is supported by the US National Institute of Mental Health (R01-MH059575) and National Institute of Drug Abuse with supplemental funding from the South African Department of Health and the University of Michigan. The Psychiatric Enquiry to General Population in Southeast Spain – Murcia (PEGASUSMurcia) Project has been financed by the Regional Health Authorities of Murcia (Servicio Murciano de Salud and Consejería de Sanidad y Política Social) and Fundación para la Formación e Investigación Sanitarias (FFIS) of Murcia. The Ukraine Comorbid Mental Disorders during Periods of Social Disruption (CMDPSD) study is funded by the US National Institute of Mental Health (RO1-MH61905). The US National Comorbidity Survey Replication (NCS-R) is supported by the National Institute of Mental Health (NIMH; U01-MH60220) with supplemental support from the National Institute of Drug Abuse (NIDA), the Substance Abuse and Mental Health Services Administration (SAMHSA), the Robert Wood Johnson Foundation (RWJF; Grant 044708), and the John W. Alden Trust. Dr Evans-Lacko currently holds a Starting Grant from the European Research Council (337673). Dr Thornicroft is supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South London at King’s College London Foundation Trust. GT acknowledges financial support from the Department of Health via the National Institute for Health Research (NIHR) Biomedical Research Centre and Dementia Unit awarded to South London and Maudsley NHS Foundation Trust in partnership with King’s College London and King’s College Hospital NHS Foundation Trust. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. GT is supported by the European Union Seventh Framework Programme (FP7/2007–2013) Emerald project. A complete list of all within-country and cross-national WMH publications can be found at http://www.hcp.med.harvard.edu/wmh/.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Treatment gap for anxiety disorders is global: Results of the World Mental Health Surveys in 21 countries

  • Alonso Caballero, Jordi
  • Liu, Zhaorui
  • Evans Lacko, Sara
  • Sadikova, Ekaterina
  • Sampson, Nancy A.
  • Chatterji, Somnath
  • Abdulmalik, Jibril
  • Aguilar Gaxiola, Sergio
  • Al-Hamzawi, Ali Obaid
  • Andrade, Laura Helena
  • Bruffaerts, Ronny
  • Cardoso, Graça
  • Cia, Alfredo H.
  • Florescu, Silvia E.
  • Girolamo, Giovanni de
  • Gureje, Oye
  • Haro Abad, Josep Maria
  • He, Yanling
  • Jonge, Peter de
  • Karam, Elie Georges
  • Kawakami, Norito
  • Kovess-Masfety, Viviane
  • Lee, Sing
  • Levinson, Daphna
  • Medina Mora, Maria Elena
  • Navarro Mateu, Fernando
  • Pennell, Beth-Ellen
  • Piazza, Marina
  • Posada Villa, José
  • Have, Margreet ten
  • Zarkov, Zahari
  • Kessler, Ronald C.
  • Thornicroft, Graham
  • WHO World Mental Health Survey Collaborators
Abstract BACKGROUND: Anxiety disorders are a major cause of burden of disease. Treatment gaps have been described, but a worldwide evaluation is lacking. We estimated, among individuals with a 12-month DSM-IV (where DSM is Diagnostic Statistical Manual) anxiety disorder in 21 countries, the proportion who (i) perceived a need for treatment; (ii) received any treatment; and (iii) received possibly adequate treatment. METHODS: Data from 23 community surveys in 21 countries of the World Mental Health (WMH) surveys. DSM-IV mental disorders were assessed (WHO Composite International Diagnostic Interview, CIDI 3.0). DSM-IV included posttraumatic stress disorder among anxiety disorders, while it is not considered so in the DSM-5. We asked if, in the previous 12 months, respondents felt they needed professional treatment and if they obtained professional treatment (specialized/general medical, complementary alternative medical, or nonmedical professional) for 'problems with emotions, nerves, mental health, or use of alcohol or drugs.' Possibly adequate treatment was defined as receiving pharmacotherapy (1+ months of medication and 4+ visits to a medical doctor) or psychotherapy, complementary alternative medicine or nonmedical care (8+ visits). RESULTS: Of 51,547 respondents (response = 71.3%), 9.8% had a 12-month DSM-IV anxiety disorder, 27.6% of whom received any treatment, and only 9.8% received possibly adequate treatment. Of those with 12-month anxiety only 41.3% perceived a need for care. Lower treatment levels were found for lower income countries. CONCLUSIONS: Low levels of service use and a high proportion of those receiving services not meeting adequacy standards for anxiety disorders exist worldwide. Results suggest the need for improving recognition of anxiety disorders and the quality of treatment.